Log in
Alphabet Inc

Alphabet Inc

Alphabet Inc · Investor
1Y performance ⓘ
+122%
AUM (13F)
$4.0B
# of Holdings
26
3Y performance ⓘ
+199%
vs S&P 500 ⓘ
+128%
Updated
Mar 31

Alphabet Inc's Alphabet Inc holds 26 U.S.-equity positions worth $4.0B (SEC 13F, Q1 2026). Top positions: CME Group Inc. 25.6%, Planet Labs PBC 24.5%, AST SpaceMobile, Inc. Class A Common Stock 18.5%. 13F-replication return is +199% over 3 years (+128 pts vs the S&P 500) — a replicated, non-audited figure.

Holdings

Stock% of portfolio SharesValue Latest activityAvg buy price Current priceDate
CME CME Group Inc. 25.6% 3.5M $1.0B NEW (+3.5M) $295.35 $245.20 (−17%) 2026-03-31
PL Planet Labs PBC 24.5% 35.2M $985M ▲ 10% (+3.3M) $3.93 $28.77 (+632%) 2026-03-31
ASTS AST SpaceMobile, Inc. Class A Common Stock 18.5% 8.9M $741M $22.74 $73.19 (+222%) 2026-03-31
RVMD Revolution Medicines, Inc. Common Stock 8.0% 3.3M $320M ▼ 1.6% (−53K) $28.68 $165.81 (+478%) 2026-03-31
ARM Arm Holdings Plc 7.4% 2.0M $297M $53.52 $407.72 (+662%) 2026-03-31
FRSH Freshworks Inc. Class A Common Stock 3.2% 16.2M $130M $15.36 $8.93 (−42%) 2026-03-31
PATH UiPath, Inc. 1.9% 7.0M $78M $17.56 $10.16 (−42%) 2026-03-31
TEM Tempus AI, Inc. Class A Common Stock 1.8% 1.6M $70M $35.00 $47.85 (+37%) 2026-03-31
PAYP Paypay Corp 1.7% 3.1M $67M NEW (+3.1M) $21.34 $13.72 (−36%) 2026-03-31
GTLB GitLab Inc. Class A Common Stock 1.5% 2.7M $59M $34.29 $25.83 (−25%) 2026-03-31
PRME Prime Medicine, Inc. Common Stock 1.4% 16.6M $58M $12.30 $3.37 (−73%) 2026-03-31
LIFE Ethos Technologies Inc. Class A Common Stock 1.1% 3.8M $42M NEW (+3.8M) $11.17 $15.53 (+39%) 2026-03-31
MAZE Maze Therapeutics, Inc. Common Stock 1.0% 1.4M $41M $11.01 $25.57 (+132%) 2026-03-31
BBOT BridgeBio Oncology Therapeutics, Inc. Common Stock 0.6% 2.8M $25M $11.58 $7.87 (−32%) 2026-03-31
RLAY Relay Therapeutics, Inc. Common Stock 0.4% 1.6M $16M $16.47 $17.28 (+5%) 2026-03-31
GLUE Monte Rosa Therapeutics, Inc. Common Stock 0.3% 684K $11M ▼ 8.1% (−61K) $7.79 $18.67 (+140%) 2026-03-31
VERA Vera Therapeutics, Inc. Class A Common Stock 0.2% 241K $10M $7.76 $38.43 (+395%) 2026-03-31
SANA Sana Biotechnology, Inc. Common Stock 0.2% 2.8M $8M $3.27 $3.36 (+3%) 2026-03-31
BEAM Beam Therapeutics Inc. Common Stock 0.2% 322K $8M $30.62 $35.53 (+16%) 2026-03-31
LYEL Lyell Immunopharma, Inc. Common Stock 0.1% 293K $6M $8.84 $11.97 (+35%) 2026-03-31
OSCR Oscar Health, Inc. 0.1% 482K $6M $6.54 $28.54 (+336%) 2026-03-31
FIG Figma, Inc. 0.1% 216K $5M $51.87 $19.08 (−63%) 2026-03-31
SPRO Spero Therapeutics, Inc. Common Stock 0.1% 890K $2M $1.45 $2.21 (+52%) 2026-03-31
HYPR Hyperfine, Inc. Class A Common Stock 0.0% 899K $971K $1.44 $1.49 (+3%) 2026-03-31
AUTL Autolus Therapeutics Plc 0.0% 698K $964K $1.84 $1.49 (−19%) 2026-03-31
TNYA Tenaya Therapeutics, Inc. Common Stock 0.0% 916K $632K $2.85 $0.70 (−75%) 2026-03-31
Related
CME stockPL stockASTS stockRVMD stockAll hedge funds
FAQ

What are Alphabet Inc's largest holdings?

As of the latest 13F: CME Group Inc. 25.6%, Planet Labs PBC 24.5%, AST SpaceMobile, Inc. Class A Common Stock 18.5%, Revolution Medicines, Inc. Common Stock 8.0%, Arm Holdings Plc 7.4%.

How big is Alphabet Inc's 13F portfolio?

$4.0B across 26 disclosed U.S.-equity positions.

What is Alphabet Inc's 3-year performance?

+199% (13F-replication, price return), +128 pts vs the S&P 500. Not an audited fund return.

Where does this data come from?

U.S. SEC Form 13F-HR institutional holdings filings.

Sourced from SEC Form 13F-HR filings · Not investment advice
SEC EDGAR 13F
Data as of 2026-03-31 · Methodology
13F-replication (price return, filing-date based) — not an audited fund return.
Published by WealthFile · Not investment advice.

Latest activity = change vs. the prior 13F. Avg buy price = est. entry over the trailing 3 years (gain = vs. latest price). Returns are 13F-replication, not audited fund returns. Sourced from SEC 13F filings.